Capacity Enhances Their In Vivo Antigen-Presenting Colony-Stimulating Factor Gene Potently Granulocyte-Macrophage Marrow-Derived Dendritic Cells with the Transfection of Immature Murine Bone

[1]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[2]  M. Roth,et al.  Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. , 1998, Cancer research.

[3]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[4]  A. Dietz,et al.  High efficiency adenovirus-mediated gene transfer to human dendritic cells. , 1998, Blood.

[5]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[6]  S. Rafii,et al.  Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.

[7]  S. Rosenberg,et al.  Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.

[8]  B. Czerniecki,et al.  Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. , 1997, Journal of immunology.

[9]  D. Kufe,et al.  Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells , 1997, Gene Therapy.

[10]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[11]  F. Graham,et al.  Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. , 1997, Human gene therapy.

[12]  T. Blankenstein,et al.  Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. , 1997, Journal of immunology.

[13]  M. Bevan,et al.  Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.

[14]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[15]  A. Enk,et al.  Cytokines and their effects on maturation, differentiation and migration of dendritic cells , 1996, Archives of Dermatological Research.

[16]  T. Luger,et al.  Interaction of murine dendritic cells with collagen up‐regulates allostimulatory capacity, surface expression of heat stable antigen, and release of cytokines , 1996, Journal of leukocyte biology.

[17]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[18]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[19]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[20]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[21]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[22]  T. Luger,et al.  Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. , 1995, Journal of immunology.

[23]  G. Schaffner,et al.  Cancer vaccines: the interleukin 2 dosage effect. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Beissert,et al.  Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.

[25]  P. Morris,et al.  Isolation and characterization of dendritic cells from mouse heart and kidney. , 1994, Journal of immunology.

[26]  E. Jaffee,et al.  Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.

[27]  R. Gallo,et al.  Deficient antigen presentation by Langerhans cells from athymic (nu/nu) mice. Restoration with thymic transplantation or administration of cytokines. , 1993, Journal of immunology.

[28]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Soler,et al.  Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. , 1993, The Journal of clinical investigation.

[30]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[31]  S. Grabbe,et al.  Effects of immunomodulatory cytokines on the presentation of tumor-associated antigens by epidermal Langerhans cells. , 1992, The Journal of investigative dermatology.

[32]  K Zatloukal,et al.  Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Kaplan,et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.

[34]  R. Gallo,et al.  Tumor antigen presentation by murine epidermal cells. , 1991, Journal of immunology.

[35]  G. Schuler.  Epidermal Langerhans Cells , 1990 .

[36]  R. Steinman,et al.  Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells , 1989, The Journal of experimental medicine.

[37]  C. Doré,et al.  Influence of dendritic cells on tumor growth. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Steinman,et al.  Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro , 1985, The Journal of experimental medicine.

[39]  H. Grey,et al.  Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. , 1984, Journal of immunology.

[40]  D. Sachs,et al.  Epidermal Langerhans cells are derived from cells originating in bone marrow , 1979, Nature.

[41]  G. Schuler,et al.  Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. , 1997, Advances in experimental medicine and biology.

[42]  A. Enk,et al.  Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under FCS-free conditions: effect of culture conditions on the type of T cell response , 1997 .

[43]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[44]  G. Schuler,et al.  Murine epidermal Langerhans cells as a model to study tissue dendritic cells. , 1993, Advances in experimental medicine and biology.

[45]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[46]  R. M. Steinman,et al.  The Hypothesis: Lack of Tumor Antigen Presentation by Dendritic Cells In Vivo Is a Major Problem that Can Be Bypassed by , 2022 .